Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1992 Sep;107(1):165–170. doi: 10.1111/j.1476-5381.1992.tb14481.x

Pharmacodynamics of the anticonvulsant effect of oxazepam in aging BN/BiRij rats.

A M Stijnen 1, I Postel-Westra 1, M W Langemeijer 1, A Hoogerkamp 1, R A Voskuyl 1, C F van Bezooijen 1, M Danhof 1
PMCID: PMC1907588  PMID: 1330159

Abstract

1. The purpose of this investigation was to examine the influence of increasing age on the pharmacokinetics and the time course of the anticonvulsant response of oxazepam in BN/BiRij rats as an animal model of aging. 2. Oxazepam was administered intravenously in a dose of 12 mg kg-1 body weight and the anticonvulsant effect intensity was measured as elevation above baseline of a threshold for induction of localized seizure activity (TLS). Direct cortical stimulation with ramp shaped electrical pulse trains of increasing intensity was used to determine this threshold. 3. The pharmacological effect vs. time profile showed in young rats an anticonvulsant component followed by proconvulsant component which is suggestive for the occurrence of acute tolerance and/or withdrawal syndrome. With increasing age the proconvulsant component disappeared, resulting in a monophasic effect profile (anticonvulsant effect only) at the age of 35 months with significantly higher anticonvulsant effect intensity immediately following drug administration. No age-related changes in the pharmacokinetic parameters of oxazepam were observed. 4. In five animals of each age group, benzodiazepine receptor binding characteristics were determined in vitro with [3H]-flunitrazepam as a ligand. Both receptor density and affinity did not show age-related changes. Available literature data on post-receptor events do not indicate conclusive age-related changes. 5. It is concluded, that the observed change in the pharmacodynamics of anticonvulsant effect of oxazepam can be explained by the disappearance of the tolerance/withdrawal phenomenon. This is compatible with a decreased efficiency of homeostatic control mechanisms in the elderly.

Full text

PDF
165

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashton H. Benzodiazepine withdrawal: an unfinished story. Br Med J (Clin Res Ed) 1984 Apr 14;288(6424):1135–1140. doi: 10.1136/bmj.288.6424.1135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Baldwin H. A., File S. E. Reversal of increased anxiety during benzodiazepine withdrawal: evidence for an anxiogenic endogenous ligand for the benzodiazepine receptor. Brain Res Bull. 1988 May;20(5):603–606. doi: 10.1016/0361-9230(88)90219-5. [DOI] [PubMed] [Google Scholar]
  3. Barnhill J. G., Greenblatt D. J., Miller L. G., Gaver A., Harmatz J. S., Shader R. I. Kinetic and dynamic components of increased benzodiazepine sensitivity in aging animals. J Pharmacol Exp Ther. 1990 Jun;253(3):1153–1161. [PubMed] [Google Scholar]
  4. Bliding A. Effects of different rates of absorption of two benzodiazepins on subjective and objective parameters. Significance for clinical use and risk of abuse. Eur J Clin Pharmacol. 1974;7(3):201–211. doi: 10.1007/BF00560382. [DOI] [PubMed] [Google Scholar]
  5. Bowling A. C., DeLorenzo R. J. Micromolar affinity benzodiazepine receptors: identification and characterization in central nervous system. Science. 1982 Jun 11;216(4551):1247–1250. doi: 10.1126/science.6281893. [DOI] [PubMed] [Google Scholar]
  6. Castleden C. M., George C. F., Marcer D., Hallett C. Increased sensitivity to nitrazepam in old age. Br Med J. 1977 Jan 1;1(6052):10–12. doi: 10.1136/bmj.1.6052.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Concas A., Pepitoni S., Atsoggiu T., Toffano G., Biggio G. Aging reduces the GABA-dependent 36Cl- flux in rat brain membrane vesicles. Life Sci. 1988;43(22):1761–1771. doi: 10.1016/0024-3205(88)90275-5. [DOI] [PubMed] [Google Scholar]
  8. Cook P. J. Benzodiazepine hypnotics in the elderly. Acta Psychiatr Scand Suppl. 1986;332:149–158. doi: 10.1111/j.1600-0447.1986.tb08992.x. [DOI] [PubMed] [Google Scholar]
  9. Crooks J. Aging and drug disposition--pharmacodynamics. J Chronic Dis. 1983;36(1):85–90. doi: 10.1016/0021-9681(83)90047-4. [DOI] [PubMed] [Google Scholar]
  10. De Blasi A., Cotecchia S., Mennini T. Selective changes of receptor binding in brain regions of aged rats. Life Sci. 1982 Jul 26;31(4):335–340. doi: 10.1016/0024-3205(82)90412-x. [DOI] [PubMed] [Google Scholar]
  11. Dingemanse J., Sollie F. A., Breimer D. D., Danhof M. Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure. J Pharmacokinet Biopharm. 1988 Apr;16(2):203–228. doi: 10.1007/BF01062261. [DOI] [PubMed] [Google Scholar]
  12. Dingemanse J., Voskuyl R. A., Langemeijer M. W., Postel-Westra I., Breimer D. D., Meinardi H., Danhof M. Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats. Br J Pharmacol. 1990 Jan;99(1):53–58. doi: 10.1111/j.1476-5381.1990.tb14653.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ellinwood E. H., Jr, Heatherly D. G., Nikaido A. M., Bjornsson T. D., Kilts C. Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam. Psychopharmacology (Berl) 1985;86(4):392–399. doi: 10.1007/BF00427897. [DOI] [PubMed] [Google Scholar]
  14. Ellinwood E. H., Jr, Linnoila M., Easler M. E., Molter D. W. Profile of acute tolerance to three sedative anxiolytics. Psychopharmacology (Berl) 1983;79(2-3):137–141. doi: 10.1007/BF00427800. [DOI] [PubMed] [Google Scholar]
  15. Greenblatt D. J., Allen M. D., Shader R. I. Toxicity of high-dose flurazepam in the elderly. Clin Pharmacol Ther. 1977 Mar;21(3):355–361. doi: 10.1002/cpt1977213355. [DOI] [PubMed] [Google Scholar]
  16. Greenblatt D. J. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet. 1981 Mar-Apr;6(2):89–105. doi: 10.2165/00003088-198106020-00001. [DOI] [PubMed] [Google Scholar]
  17. Greenblatt D. J., Divoll M., Harmatz J. S., MacLaughlin D. S., Shader R. I. Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther. 1981 Oct;30(4):475–486. doi: 10.1038/clpt.1981.191. [DOI] [PubMed] [Google Scholar]
  18. Greenblatt D. J., Divoll M., Harmatz J. S., Shader R. I. Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther. 1980 Oct;215(1):86–91. [PubMed] [Google Scholar]
  19. Greenblatt D. J., Shader R. I. Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations. Drug Metab Rev. 1978;8(1):13–28. doi: 10.3109/03602537808993775. [DOI] [PubMed] [Google Scholar]
  20. Hauser W. A., Kurland L. T. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia. 1975 Mar;16(1):1–66. doi: 10.1111/j.1528-1157.1975.tb04721.x. [DOI] [PubMed] [Google Scholar]
  21. Heusner J. E., Bosmann H. B. GABA stimulation of 3H-diazepam binding in aged mice. Life Sci. 1981 Aug 31;29(9):971–974. doi: 10.1016/0024-3205(81)90400-8. [DOI] [PubMed] [Google Scholar]
  22. Hollander-Jansen M., Dingemanse J., Langemeijer M. W., Danhof M. Relationship between receptor occupancy at 37 degrees C and the anticonvulsant effect of flunitrazepam in rats. Pharm Res. 1989 Jul;6(7):585–591. doi: 10.1023/a:1015901414495. [DOI] [PubMed] [Google Scholar]
  23. Ito Y., Ho I. K., Hoskins B. Cerebellar GABAA and benzodiazepine receptor characteristics in young and aged mice. Brain Res Bull. 1988 Aug;21(2):251–255. doi: 10.1016/0361-9230(88)90239-0. [DOI] [PubMed] [Google Scholar]
  24. Kanto J., Kangas L., Aaltonen L., Hilke H. Effect of age on the pharmacokinetics and sedative of flunitrazepam. Int J Clin Pharmacol Ther Toxicol. 1981 Sep;19(9):400–404. [PubMed] [Google Scholar]
  25. Kitani K., Klotz U., Kanai S., Sato Y., Ohta M., Nokubo M. Age-related differences in the coordination disturbance and anticonvulsant effect of oxazepam in mice. Arch Gerontol Geriatr. 1989 Jul;9(1):31–43. doi: 10.1016/0167-4943(89)90022-8. [DOI] [PubMed] [Google Scholar]
  26. Lister R. G., Nutt D. J. Mice and rats are sensitized to the proconvulsant action of a benzodiazepine-receptor inverse agonist (FG 7142) following a single dose of lorazepam. Brain Res. 1986 Aug 6;379(2):364–366. doi: 10.1016/0006-8993(86)90791-2. [DOI] [PubMed] [Google Scholar]
  27. MacLeod S. M., Giles H. G., Patzalek G., Thiessen J. J., Sellers E. M. Diazepam actions and plasma concentrations following ethanol ingestion. Eur J Clin Pharmacol. 1977;11(5):345–349. doi: 10.1007/BF00566531. [DOI] [PubMed] [Google Scholar]
  28. Medina J. H., de Stein M. L., De Robertis E. n-[3H]butyl-beta-carboline-3-carboxylate, a putative endogenous ligand, binds preferentially to subtype 1 of central benzodiazepine receptors. J Neurochem. 1989 Mar;52(3):665–670. doi: 10.1111/j.1471-4159.1989.tb02506.x. [DOI] [PubMed] [Google Scholar]
  29. Murray T. G., Chiang S. T., Koepke H. H., Walker B. R. Renal disease, age, and oxazepam kinetics. Clin Pharmacol Ther. 1981 Dec;30(6):805–809. doi: 10.1038/clpt.1981.241. [DOI] [PubMed] [Google Scholar]
  30. Novas M. L., Wolfman C., Medina J. H., de Robertis E. Proconvulsant and 'anxiogenic' effects of n-butyl beta carboline-3-carboxylate, an endogenous benzodiazepine binding inhibitor from brain. Pharmacol Biochem Behav. 1988 Jun;30(2):331–336. doi: 10.1016/0091-3057(88)90463-7. [DOI] [PubMed] [Google Scholar]
  31. Ochs H. R., Greenblatt D. J., Otten H. Disposition of oxazepam in relation to age, sex, and cigarette smoking. Klin Wochenschr. 1981 Aug 17;59(16):899–903. doi: 10.1007/BF01721923. [DOI] [PubMed] [Google Scholar]
  32. Reidenberg M. M., Levy M., Warner H., Coutinho C. B., Schwartz M. A., Yu G., Cheripko J. Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin Pharmacol Ther. 1978 Apr;23(4):371–374. doi: 10.1002/cpt1978234371. [DOI] [PubMed] [Google Scholar]
  33. Salzman C., Shader R. I., Greenblatt D. J., Harmatz J. S. Long v short half-life benzodiazepines in the elderly. Kinetics and clinical effects of diazepam and oxazepam. Arch Gen Psychiatry. 1983 Mar;40(3):293–297. doi: 10.1001/archpsyc.1983.01790030063008. [DOI] [PubMed] [Google Scholar]
  34. Sisenwine S. F., Tio C. O., Shrader S. R., Ruelius H. W. The biotransformation of oxazepam (7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one) in man, miniature swine and rat. Arzneimittelforschung. 1972 Apr;22(4):682–687. [PubMed] [Google Scholar]
  35. Sisenwine S. F., Tio C. O. The metabolic disposition of oxazepam in rats. Drug Metab Dispos. 1986 Jan-Feb;14(1):41–45. [PubMed] [Google Scholar]
  36. Stijnen A. M., Danhof M., Van Bezooijen C. F. Increased sensitivity to the anesthetic effect of phenobarbital in aging BN/BiRij rats. J Pharmacol Exp Ther. 1992 Apr;261(1):81–87. [PubMed] [Google Scholar]
  37. Swift C. G., Ewen J. M., Clarke P., Stevenson I. H. Responsiveness to oral diazepam in the elderly: relationship to total and free plasma concentrations. Br J Clin Pharmacol. 1985 Aug;20(2):111–118. doi: 10.1111/j.1365-2125.1985.tb05040.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Swift C. G., Swift M. R., Ankier S. I., Pidgen A., Robinson J. Single dose pharmacokinetics and pharmacodynamics of oral loprazolam in the elderly. Br J Clin Pharmacol. 1985 Aug;20(2):119–128. doi: 10.1111/j.1365-2125.1985.tb05041.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Voskuyl R. A., Dingemanse J., Danhof M. Determination of the threshold for convulsions by direct cortical stimulation. Epilepsy Res. 1989 Mar-Apr;3(2):120–129. doi: 10.1016/0920-1211(89)90039-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES